DCP, MRP, centralised or national: how to choose the EU registration route

There are four ways to obtain a marketing authorisation in the EU: a national procedure, the decentralised procedure (DCP), the mutual recognition procedure (MRP) and the centralised procedure. For some products the law makes the choice.

Read more about what this guide covers

For most generics and established substances the applicant chooses, and the choice fixes who assesses the dossier, how many licences come out of it, what the fees are and how every later variation is filed. This guide sets out the legal basis and scope of each route, gives a decision path, compares the routes side by side, and covers what can still be changed later through repeat use and duplicates.

16 min readUpdated 13 primary sources

Reviewed by Gosia Luksza, CEO at Regunaut

Key figures
Assessment time in the national, decentralised (120 + 90) and centralised routes
210 days
Mutual recognition: the RMS updates its report, then the CMS recognise
90 + 90 days
For each national decision once a DCP or MRP has closed
30 days
From the centralised route, against one national authorisation per country from the others
1 licence

In short

  • Products in the Annex to Regulation (EC) No 726/2004 must use the centralised procedure; everything else goes national, DCP or MRP unless EMA confirms eligibility under Article 3(2).
  • DCP is for a product not yet authorised anywhere in the EU; MRP starts from an existing national authorisation and is also the route for later repeat-use waves.
  • The centralised route gives one licence and one product information text for the whole EU; DCP and MRP give one national authorisation per country, kept in step through the reference Member State.
  • The route fixes the fee structure and the maintenance model for the life of the product, so price it and plan the later variations before choosing, not after.

Each section opens with its main point. Open the ones you need.

The four routes and their legal bases

Article 6(1) of Directive 2001/83/EC allows a medicine onto the market of a Member State only with a marketing authorisation, issued either by that Member State's competent authority under the directive or by the European Commission under Regulation (EC) No 726/2004. Those two acts provide four routes.

Read more about The four routes and their legal bases
  • National procedure. One application to one competent authority for one Member State, decided within 210 days of a valid application (Article 17(1) of the directive). The glossary entry on the national procedure covers it in detail.
  • Decentralised procedure (DCP). For a product not yet authorised in any Member State and wanted in several. An identical dossier goes to all of them; the reference Member State (RMS) chosen by the applicant drafts the assessment within 120 days and the concerned Member States (CMS) have 90 days to agree (Article 28(1), (3) and (4)). See the glossary entry on the DCP.
  • Mutual recognition procedure (MRP). For a product that already holds a national authorisation. That Member State acts as RMS and updates its assessment report within 90 days, and the CMS recognise the authorisation within a further 90 days (Article 28(2) and (4)). See the glossary entry on the MRP.
  • Centralised procedure. One application to the European Medicines Agency (EMA), an opinion from the Committee for Medicinal Products for Human Use (CHMP) within 210 days of a valid application (Article 6(3) of the regulation) and one Commission decision valid in every Member State.

The day counts are assessment time, not calendar time: in every route the clock stops while the applicant answers questions. The DCP timetable guide follows one procedure day by day. This guide is about choosing between the routes.

Who must, and who may, use the centralised procedure

The first question is whether the law has already chosen. Article 3(1) of Regulation (EC) No 726/2004 bars a product listed in the Annex from the market without a Union authorisation, so for these products the centralised procedure is the only route.

Read more about Who must, and who may, use the centralised procedure
  • Medicines developed by one of three biotechnological processes: recombinant DNA technology, controlled expression of genes in prokaryotes and eukaryotes, and hybridoma and monoclonal antibody methods (Annex, point 1).
  • Advanced therapy medicinal products as defined in Regulation (EC) No 1394/2007 (point 1a).
  • Medicines containing a new active substance for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions, or viral diseases (point 3).
  • Medicines designated as orphan medicinal products under Regulation (EC) No 141/2000 (point 4).

Article 3(2) opens the route, at the applicant's request, to two further groups: products containing an active substance that was not authorised in the Union on 20 May 2004, and products for which the applicant shows a significant therapeutic, scientific or technical innovation, or that a Union authorisation is in the interest of patients at Union level. Eligibility under this optional scope is not automatic. EMA decides on a justified eligibility request, which it recommends sending at the earliest 18 months and at the latest seven months before the application is filed. Seven months ahead is also when applicants notify EMA of their intention to submit and ask for the rapporteur and co-rapporteur to be appointed.

Mandatory means no fallback

A product within the Annex cannot be authorised nationally, by DCP or by MRP, even for a single country. Check the active substance against point 3 and the manufacturing process against point 1 before any national slot is booked.

Generics of centrally authorised products

A generic or hybrid of a centrally authorised reference product has automatic access to the centralised procedure under Article 3(3). The applicant does not have to take it. The same paragraph lets the Member States authorise such a generic under Directive 2001/83/EC, through a national procedure, a DCP or an MRP, on three conditions.

Read more about Generics of centrally authorised products
  • The application is submitted under Article 10 of Directive 2001/83/EC.
  • The summary of product characteristics (SmPC) is consistent in all relevant respects with that of the centrally authorised product, except for the parts on indications or dosage forms still covered by patent law when the generic is marketed.
  • The generic is authorised under the same name in every Member State where the application is made. All linguistic versions of the international non-proprietary name count as the same name.

The choice is commercial as much as regulatory. The centralised route gives the generic one licence for all Member States and one product information text, at EMA's fees. A DCP lets the company pick only the markets it will supply and pay only those agencies, but the third condition removes the freedom to use a different name in each country that other DCP products have. A generic of a nationally authorised reference product has no automatic access: EMA accepts it into the centralised procedure only if the applicant shows that it qualifies under Article 3(2)(b). The glossary entry on generic applications covers the legal basis itself.

A decision path in five questions

Five questions, asked in this order, settle the route in most cases.

  1. Question 1

    Is the product in the Annex?

    If it is made by one of the listed biotechnological processes, is an advanced therapy, is a designated orphan medicine or contains a new active substance for one of the listed diseases, the centralised procedure is mandatory and the remaining questions do not apply.

  2. Question 2

    Could it use the centralised procedure, and would you want it to?

    A new active substance, a demonstrable innovation or a generic of a centrally authorised product can go to EMA. The route pays off when the product will be supplied in most Member States under one name and one product information text. If only a few markets matter, compare EMA's fees with the sum of the national fees for those markets.

  3. Question 3

    How many Member States, and when?

    One market with no plans beyond it: a national procedure. Two or more: DCP or MRP, because Articles 17(2) and 18 of the directive stop a second Member State from handling the same product in a separate national procedure.

  4. Question 4

    Is the product already authorised in a Member State?

    If yes, that authorisation is the starting point and the route is MRP, with that Member State as RMS. If no, the route is DCP and the applicant chooses the RMS.

  5. Question 5

    Which markets go in the first wave?

    Each CMS adds a fee, a set of translations and a national phase. Markets left out can be added later by repeat use, at the price of a further procedure. Decide the first wave on launch plans, then check RMS slot availability and the reference product's protection in each country.

Ask before you book

Where the legal basis, the reference product or the eligibility is open to argument, settle it first: an eligibility request to EMA for the centralised route, or a pre-submission exchange with the intended RMS for a DCP. Changing route after submission means withdrawing and starting again.

The four routes side by side

National, decentralised, mutual recognition and centralised procedures compared
NationalDecentralised (DCP)Mutual recognition (MRP)Centralised
EligibilityOutside the centralised mandatory scope; one Member State only; not authorised or under assessment in another (Art. 17(2) and 18)Outside the mandatory scope; not yet authorised in any Member State; two or more Member States (Art. 28(1) and (3))Already authorised in one Member State and wanted in others (Art. 28(2)); also the route for repeat useMandatory for Annex products; optional under Art. 3(2); automatic access for generics of centrally authorised products
Who assessesThe national competent authorityThe RMS drafts the assessment; the CMS comment and must agree; the CMDh handles disagreementsThe RMS updates its assessment report; the CMS recognise it; the CMDh handles disagreementsThe CHMP at EMA, through a rapporteur and co-rapporteur; the European Commission decides
Legal timetable210 days (Art. 17(1))120 days for the RMS draft, then 90 days for the CMS (Art. 28(3) and (4))90 days for the RMS update, then 90 days for recognition (Art. 28(2) and (4))210 days to the CHMP opinion (Art. 6(3)); EMA gives 67 days for the Commission decision
OutcomeOne national authorisationOne national authorisation per Member State, each within 30 days of closure (Art. 28(5))One national authorisation per new Member State, each within 30 days of closureOne Union authorisation valid in every Member State, extended to Iceland, Liechtenstein and Norway
Product informationApproved in the national languageCommon texts agreed in the procedure; national translations in each Member State's national phaseThe RMS texts, recognised unchanged; national translations in the national phaseOne text in all official EU languages, with a single invented name
Later variationsFiled with that one authorityRun through the same RMS for all Member States concernedRun through the same RMS for all Member States concernedFiled once, with EMA, for the whole EU
FeesOne agency's feeRMS fee plus a fee in every CMSRMS fee for the report update plus a fee in every CMSEMA application fee, then an annual fee

The trade-off is control against coverage. DCP and MRP let the company choose its markets and hold a separate licence in each, which can be withdrawn or transferred country by country. The centralised route covers the whole EU in one step and removes the national phase, but the company cannot leave markets out and cannot vary the product for one country. The glossary entries on the centralised procedure, the RMS and the CMS describe the roles in each.

What the choice means for fees, slots and maintenance

Fees follow the procedure. A national application is priced by one agency. In a DCP or MRP the RMS charges an assessment fee and every CMS charges its own, so the total is the sum of the markets chosen, and most national schedules add a supplement for each further strength or pharmaceutical form. A centralised application is priced by EMA instead of per market, and EMA charges an annual fee for each authorisation afterwards. The legal basis moves the amount as well: a generic application is usually priced below a full dossier. The glossary entries on national agency fees and EMA fees describe the two systems.

Read more about What the choice means for fees, slots and maintenance

Capacity is the second constraint. A DCP cannot start until the RMS has a slot, and agencies differ in how far ahead they are booked. An MRP or a repeat-use wave depends on the RMS finding time to update its assessment report. The centralised procedure has no slots, but it runs to EMA's published submission dates and the CHMP meeting calendar, with the intention to submit notified seven months ahead.

A DCP or MRP ends with national decisions, not with a licence. Each Member State has 30 days from the close of the procedure to grant its authorisation, and it needs the national translations of the agreed product information, with any mock-ups and national pack details it requires, before it does. The centralised route replaces that step with one linguistic review of all language versions after the CHMP opinion and a single Commission decision.

The route also sets the maintenance model for the life of the product. A centrally authorised product has one holder, one invented name and one product information text, and every variation, renewal and transfer is filed once, with EMA. A DCP or MRP product is a set of national authorisations held in step: variations and renewals run through the same RMS for all the Member States concerned and the product information stays harmonised, yet each national authorisation can be withdrawn, transferred or left to lapse under the sunset clause country by country. Purely national authorisations in several countries share nothing, so every change is filed separately in each.

Extending and changing later: repeat use, duplicates and switching route

The first wave need not be the last. After a DCP or MRP has closed, the holder can use mutual recognition again, for new CMS or for a CMS that was withdrawn from the earlier procedure. The CMDh calls this repeat use and sets no limit on the number of waves until every Member State is included. The conditions are practical: all ongoing variations finished, the dossier updated to current requirements and, after a DCP, the national authorisation granted in the RMS. A repeat-use procedure can then start 30 days after the first procedure ends.

Read more about Extending and changing later: repeat use, duplicates and switching route

The new CMS must recognise the product with the identical SmPC, labelling and package leaflet, and points settled in the earlier procedure should not be reopened without justified reasons. An old dossier is the main risk. Standards met at the first approval may no longer satisfy a new Member State, which can then raise a potential serious risk to public health and trigger a referral to the CMDh and the CHMP.

A duplicate is a second, independent authorisation built on the same dossier and the same legal basis under a different name, for the same or a different holder, usually for co-marketing. In DCP and MRP the CMDh recommendations rest on one rule: a CMS cannot recognise the RMS authorisation more than once. A duplicate from the same or a linked company therefore has to be authorised in the RMS first and then mutually recognised, or run as its own DCP with the same RMS. Each duplicate is then varied independently, although the CMDh encourages holders to keep the product information aligned. In the centralised procedure, Article 82(1) of the regulation allows one authorisation per applicant for a product; the Commission accepts a further application only for objective, verifiable public health reasons relating to availability, or for co-marketing, and EMA asks for the request about four months before submission.

Moving between routes is narrower. A national authorisation becomes the basis of an MRP when the holder wants further Member States, and fresh national applications elsewhere are not a way round it. The RMS can be changed with the agreement of the authorities involved, which matters when the product is no longer marketed in the RMS. There is no procedure that converts national authorisations into a centralised one: that takes a new application, eligible in its own right under Article 3.

Common mistakes when choosing a route

  • Assuming eligibility. An optional-scope product is not in the centralised procedure until EMA confirms it, and a plan built on an unconfirmed eligibility loses months when the answer is no.
  • Filing nationally in two countries. Separate national applications for the same product are not an alternative to DCP or MRP: the second Member State declines to assess the application or rejects it under Articles 17(2) and 18.
  • Reading day counts as calendar time. 210 days of assessment is typically a year or more once validation, clock-stops and the national phase or the Commission decision are added.
  • Choosing the RMS for its slot alone. The RMS leads every later variation, renewal and repeat-use wave, so its handling of post-authorisation work matters as much as its start date.
  • Leaving markets out to save fees. Each repeat-use wave carries its own RMS work and CMS fees and needs a fully varied, up-to-date dossier, so several small waves usually cost more than one larger first wave.
  • Starting an MRP from an old national dossier. The RMS has to update its assessment report first, and gaps against current standards surface in front of the new CMS.
  • Forgetting the name rule for generics of centrally authorised products. Filed through a DCP, the generic must carry the same name in every Member State concerned.

Check protection before the route

A generic or hybrid application can only be filed once the reference product's data exclusivity has expired, whichever route is used. Confirm the reference product, the date of its first authorisation in the EU and its status in each intended Member State before fixing the first wave.

What the agreed 2026 EU pharma package changes

Today

Four routes under Directive 2001/83/EC and Regulation (EC) No 726/2004. The CHMP opinion is due within 210 days, and authorisations are valid for five years before renewal.

Agreed text

The same four routes. The CHMP opinion is due within 180 days, or 150 days under accelerated assessment (Article 7(6) and (7) of the Council's position on the regulation), and authorisations are valid for an unlimited period from grant (Article 49 of the directive; Article 18 of the regulation).

The agreed EU pharma package (not yet in force) keeps the architecture described here. The directive retains the national procedures, the reference Member State model and the CMDh. The regulation repeals Regulation (EC) No 726/2004 and carries the centralised procedure forward, bringing the orphan and paediatric regulations into the same act (Article 185). Our overview of the new pharmaceutical regulation covers the centralised changes, including a provision that lets the CHMP end an assessment early when the data are not mature enough (Article 11(2)).

Read more about What the agreed 2026 EU pharma package changes

Three points bear on the choice of route. The centralised assessment time falls to 180 days; the day counts for the national procedures should be checked against the published act. Unlimited validity by default removes most routine renewals on every route, which lightens the upkeep of a large set of national authorisations; see MA validity changes. And variation applications for national authorisations are to be made electronically in EMA formats (Article 94 of the directive), as set out in variations changes. The protection periods are the same whichever route a product takes (Article 30 of the regulation).

Under the agreed text most provisions apply 24 months after entry into force, and centralised applications still pending at that point are completed under the current 210-day timetable (Article 186(2)). Article numbers follow the Council's position of 28 September 2026 and may change in the act published in the Official Journal. The legislative timeline tracks each step.

Put this guide to work

The jobs in the Regunaut platform that apply what this guide covers to your own product.

Terms used in this guide

Common questions

Choosing the EU route: what teams ask

What is the difference between DCP and MRP?

Both end in national authorisations co-ordinated by a reference Member State under Article 28 of Directive 2001/83/EC. The decentralised procedure is for a product not yet authorised in any Member State: the RMS drafts the assessment in 120 days and the concerned Member States agree within 90. Mutual recognition starts from an existing national authorisation: the RMS updates its assessment report within 90 days and the other Member States recognise it within 90.

What is the difference between the centralised and the decentralised procedure?

The centralised procedure is one application to EMA, assessed by the CHMP, ending in a single Commission decision valid in every Member State with one product information text. The decentralised procedure is run by national authorities for the Member States the applicant selects and ends in one national authorisation per country. Products in the Annex to Regulation (EC) No 726/2004 must use the centralised route; most generics use the decentralised one.

Which procedure should a generic use?

Most generics of nationally authorised reference products use a DCP for the first wave of markets and repeat-use MRP waves afterwards. A generic of a centrally authorised product can choose: automatic access to the centralised procedure under Article 3(3) of Regulation (EC) No 726/2004, or a national route, where it must carry the same name in every Member State concerned and an SmPC consistent with the reference product's.

Which medicines must use the centralised procedure?

Those in the Annex to Regulation (EC) No 726/2004: medicines made by the listed biotechnological processes, advanced therapy medicinal products, designated orphan medicines, and new active substances for AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions, and viral diseases. Other new active substances and demonstrable innovations may use it if EMA confirms eligibility under Article 3(2).

Can we file separate national applications in several Member States?

Not for the same product. Under Article 17(2) of Directive 2001/83/EC a Member State that finds the application is under examination elsewhere declines to assess it, and under Article 18 it rejects an application for a product already authorised in another Member State unless it came through the decentralised or mutual recognition procedure. One market means a national procedure; two or more mean DCP or MRP.

What is a repeat-use procedure?

It is the mutual recognition procedure used again after a first DCP or MRP has closed, to add Member States that were not in the earlier wave or were withdrawn from it. The RMS stays the same and updates its assessment report, and the new Member States recognise the product with the identical SmPC, labelling and package leaflet. The CMDh sets no limit on the number of waves, but ongoing variations must be finished first.

Sources

Article numbers refer to the Council's position at first reading of 28 September 2026 (ST 7106/2/26 REV 2 for the directive, ST 7105/2/26 REV 2 for the regulation), which reflects the political agreement of December 2025. Numbering may change in the act published in the Official Journal.

  1. EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products, consolidated text, Articles 3, 6, 10 and 82 and the Annex
  2. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text, Articles 6, 17, 18 and 28 to 29
  3. European Medicines Agency: Authorisation of medicines
  4. European Medicines Agency: Pre-authorisation guidance for users of the centralised procedure
  5. CMDh: Procedural advice on Repeat-Use (CMDh/008/2009, Rev. 11, January 2025)
  6. CMDh: Recommendations on Multiple/Duplicate Applications in Mutual Recognition and Decentralised Procedures (Rev. 4, May 2016)
  7. Council of the EU: Position at first reading on the Directive on the Union code relating to medicinal products for human use, adopted 28 September 2026 (ST 7106/2/26 REV 2)
  8. Council of the EU: Position at first reading on the Regulation laying down Union procedures for the authorisation and supervision of medicinal products, adopted 28 September 2026 (ST 7105/2/26 REV 2)
  9. Council of the EU: 'Pharma package': Council and Parliament reach a deal (press release, 11 December 2025)
  10. Council of the EU: The pharma package, new EU rules on medicines (policy page)
  11. European Commission: Reform of the EU pharmaceutical legislation
  12. EUR-Lex: Procedure 2023/0132/COD, Directive on the Union code relating to medicinal products for human use (COM(2023) 192)
  13. EUR-Lex: Procedure 2023/0131/COD, Regulation on Union procedures for the authorisation and supervision of medicinal products (COM(2023) 193)

Price the route before you commit to it

Fee Calculation breaks a national, DCP, MRP or centralised filing down country by country, with the source behind every fee line.

Compare fees by route and market

Set the procedure, the markets and the product details, and see each agency's fee lines, sources and payment instructions.

Try for free

Talk the route through

30 minutes on your pipeline: which route fits each product and what the first wave of markets will cost.

Book a demo